• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Cannabis

Seelos Therapeutics Seeks Suicide Solution in Ketamine

It's a wonder how many lives could be saved if patients were given this drug at a time of dire need.
By DEBRA BORCHARDT
Dec 11, 2020 | 10:00 AM EST
Stocks quotes in this article: SEEL

Suicide is a difficult subject that often gets pushed to the side because, well, it's depressing. Rates of suicide in the U.S. are at a more than 20-year high, according to a Princeton research article. Often suicides aren't reported on the news because of a fear of suicide contagion. This research suggested "spread of suicide-related thoughts and behaviors through exposure to sensationalized and harmful content is a well-recognized phenomenon."

As a result it is surprising to learn that according to the research, "Annually, there are nearly 500,000 Emergency Department visits for self-harm, and rates of such injuries have risen by more than 39% from 2001 to 2017. Furthermore, national survey data indicate that the total number of Americans at risk for suicide is even greater; more than 10.5 million Americans experience serious thoughts of suicide each year."

One company willing to tackle such a difficult subject is the biotech company Seelos Therapeutics  (SEEL) . The company has designed a study for acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) beginning in the fall of 2020 using Intranasal Racemic Ketamine (SLS-002). Seelos is planning to initiate this proof of concept study in two parts: Part A is an open-label study of 16 patients, and will be followed by Part B which is a double blind, placebo-controlled study of approximately 120 patients.

Raj Mehra, Ph.D., Chairman and CEO of Seelos said at the time, "It is heartening to see that all intranasal doses were judged to be generally safe and well tolerated, and the resolution of dissociative side-effect among all doses by the one hour timepoint for this group mean affords that this therapy is truly differentiated, which enables Seelos to evaluate SLS-002 in indications beyond ASIB, such as first line MDD."

The company's goal is to have the drug available in hospitals to treat suicidal patients when they are in the emergency room. Currently most suicidal patients enter the hospital where they are stabilized for a short time and then are often transferred to a mental hospital. However, without insurance many patients are often released back into society and having had no real resolution to the problem.

A study by Dr. Kyle Lapidus, et al. at Mt Sinai in 2014 has shown significant improvement in depressive symptoms at 24 hours after ketamine compared to a placebo. The company found that its intranasal ketamine was well tolerated with minimal adverse side effects.

Currently, suicidal patients are often given anti-depressant drugs that actually come with a warning that it may cause suicidal thoughts. These drugs are also slow acting, whereas patients respond to this ketamine within hours. Seelos sees this as an unmet opportunity and one that it is willing to take on. While other companies are being judged on the relative ease with which ketamine is handed out at clinics, Seelos says it wants no part of the storefront ketamine world.

In addition to its ketamine work, Seelos was granted Orphan Drug Designation (ODD) for SLS-005 in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) from the FDA. Seelos said its Phase IIb/III trial plans to enroll 160 patients with either familial or sporadic ALS in a double-blind placebo-controlled trial. SLS-005 was previously granted Orphan Drug Designation from the FDA and the European Medicines Agency (EMA) for Sanfilippo syndrome, spinocerebellar ataxia type 3 (SCA3) and oculopharyngeal muscular dystrophy (OPMD).

While lots of focus has been heaped on clinic companies serving up ketamine treatments, Seelos is quietly building its reputation as a solution to a terrible problem. It's a wonder how many lives could be saved if they were given this drug at a time of dire need.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Debra Borchardt had no position in the securities mentioned.

TAGS: Investing | Stocks | Trading | Pharmaceuticals | Cannabis

More from Cannabis

Want to Invest in Constellation Brands? Wait for a Discount

Stephen Guilfoyle
Apr 6, 2023 11:10 AM EDT

The quarter wasn't great, but the guidance was promising.

Doug Kass: Cannabis Stocks Are Still Not SAFE

Doug Kass
Dec 20, 2022 11:15 AM EST

Though it is tempting, there are a host of reasons why I'm not bottom fishing.

Cannabis ETFs Could Soon Turn a New Leaf

Mark Abssy
Dec 8, 2022 1:11 PM EST

With likely passage of new legislation, the pot industry might have a remedy for the nausea it gave investors.

3 Market Sectors Are Likely to Be Most Impacted by the Midterm Election

James "Rev Shark" DePorre
Nov 8, 2022 6:22 AM EST

The focus is on positioning for the election and CPI Thursday.

I'm Monitoring a Cannabis ETF That's Showing Signs of Bottoming

Bob Byrne
Nov 7, 2022 8:04 AM EST

It's a dicey play as the price action isn't defined as yet and the ETF still could break lower.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 06:54 PM EDT CHRIS VERSACE

    AAP Podcast: A Tongue -- and a Market -- Twister: 'Get a Debt Deal Done'

    Listen in as the Action Alerts PLUS Podcast tackle...
  • 12:07 PM EDT STEPHEN GUILFOYLE

    Selling Some of This Surging AI-Related Stock

    This isn't the only name in the Stocks Under $10 p...
  • 09:48 AM EDT CHRIS VERSACE

    AAP Podcast With Portillo's CEO!

    Listen in as we talk with a rising star in the Chi...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login